James M Ford
ECOG-ACRIN Cancer Research Group · Stanford University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name James M Ford as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:52 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05564377 · Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNational Cancer Institute (NCI) · recruiting · Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 · principal investigator
- N/ANCT02215928 · Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid TumorsStanford University · recruiting · Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
- N/ANCT01650922 · Molecular Genetic Studies of Childhood Brain Tumors and Blood SamplesStanford University · completed · Brain Cancer · principal investigator
- N/ANCT01048281 · Clinical & Pathological Studies of Upper Gastrointestinal CarcinomaStanford University · recruiting · Stomach Cancer, Gastro-Esophageal(GE) Junction Cancer, Gastric (Stomach) Cancer · principal investigator
- N/ANCT01034033 · Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood SamplesStanford University · recruiting · Breast Cancer, Ovarian Cancer, Gynecologic Cancers · principal investigator
- N/ANCT00255060 · Comprehensive Screening for Women at High Genetic Risk for Developing Breast CancerStanford University · completed · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 39 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Cancer Research Training and Education CoordinationP30CA124435 · NCI · STANFORD UNIVERSITY · fiscal years 2022 to 2025 · $169,872 awarded in 2025Same name and institution; not confirmed by an ID
- Stagewise Implementation-To-Target- Medications for Addiction Treatment (SITT-MAT)R01DA052975 · NIDA · STANFORD UNIVERSITY · fiscal years 2021 to 2025 · $630,346 awarded in 2025Same name and institution; not confirmed by an ID
- Precancer Atlas of Familial Adenomatous PolyposisU2CCA233311 · NCI · STANFORD UNIVERSITY · fiscal years 2018 to 2023 · $970,941 awarded in 2023Same name and institution; not confirmed by an ID
- Using NIATx Strategies to Implement Integrated Services in Routine CareR01DA037222 · NIDA · STANFORD UNIVERSITY · fiscal years 2015 to 2019 · $548,807 awarded in 2019Same name and institution; not confirmed by an ID
- Training Program in Investigative OncologyT32CA009287 · NCI · STANFORD UNIVERSITY · fiscal years 2008 to 2012 · $383,777 awarded in 2012Same name and institution; not confirmed by an ID
- A High-Throughput Assay for DNA Repair Activity in the Presence of AberrantBRCA1R21NS061674 · NINDS · STANFORD UNIVERSITY · fiscal years 2010 · $160,000 awarded in 2010Same name and institution; not confirmed by an ID
- Ubiquitin-Mediated Regulation of DNA RepairR01CA108794 · NCI · STANFORD UNIVERSITY · fiscal years 2004 to 2007 · $279,902 awarded in 2007Same name and institution; not confirmed by an ID
- Genome-Wide Allelic Imbalances in Colon CancerR21CA109190 · NCI · STANFORD UNIVERSITY · fiscal years 2005 to 2006 · $131,847 awarded in 2006Same name and institution; not confirmed by an ID
- MECHANISM FOR P53-DEPENDENT DNA EXCISION REPAIRR01CA083889 · NCI · STANFORD UNIVERSITY · fiscal years 2000 to 2002 · $221,596 awarded in 2002Same name and institution; not confirmed by an ID
- Workshop on DNA Repair and related DNA transactionsR13CA093586 · NCI · STANFORD UNIVERSITY · fiscal years 2001 · $9,000 awarded in 2001Same name and institution; not confirmed by an ID
- ROLE OF P53 GENE IN CELLULAR SENSITIVITY TO DNA DAMAGEK08CA064330 · NCI · STANFORD UNIVERSITY · fiscal years 1994 to 1998 · $91,109 awarded in 1998Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT05564377
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:52 UTC. The ranking covers the 200 most relevant of 62 PubMed records, and a shared surname and initials can bring in a namesake. All 62 on PubMed
- Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.N Engl J Med · 20014,063 citationsRCR 75.7
- 2,201 citationsRCR 40.7
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.Clin Cancer Res · 2016919 citationsRCR 25.8
- ERPs to response production and inhibition.Electroencephalogr Clin Neurophysiol · 1985466 citationsRCR 17.1
- 399 citationsRCR 26.2
- Combined event-related fMRI and EEG evidence for temporal-parietal cortex activation during target detection.Neuroreport · 1997280 citationsRCR 8.9
- Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.Int J Radiat Oncol Biol Phys · 2008269 citationsRCR 7.0
- Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.Int J Radiat Oncol Biol Phys · 2005252 citationsRCR 6.5
- 226 citationsRCR 6.2
- 206 citationsRCR 5.5